Mounting studies have shown that pre-albumin(PA) and fibrinogen regulate the occurrence and development of various tumors, and their levels in peripheral blood are closely related to the patient's survival and sensitivity to therapy [31, 32].As a novel, effective, economical and practical biomarker, the fibrinogen to pre-albumin ratio (FPR) is not only gradually used to evaluate the prognosis of digestive system tumors such as colorectal cancer [20], hepatocellular carcinoma [16] and gastric cancer [13], but also as an index to predict the prognosis of lung [33] and bladder cancer [34]. This evidence concerns the gene ALB and urinary bladder cancer.